AR081376A1 - Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso - Google Patents
Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su usoInfo
- Publication number
- AR081376A1 AR081376A1 ARP110101590A ARP110101590A AR081376A1 AR 081376 A1 AR081376 A1 AR 081376A1 AR P110101590 A ARP110101590 A AR P110101590A AR P110101590 A ARP110101590 A AR P110101590A AR 081376 A1 AR081376 A1 AR 081376A1
- Authority
- AR
- Argentina
- Prior art keywords
- angiotensin
- combination
- receptor
- antagonists
- xantina
- Prior art date
Links
- 102000008873 Angiotensin II receptor Human genes 0.000 title 1
- 108050000824 Angiotensin II receptor Proteins 0.000 title 1
- 102000004316 Oxidoreductases Human genes 0.000 title 1
- 108090000854 Oxidoreductases Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 2
- 239000002083 C09CA01 - Losartan Substances 0.000 abstract 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 abstract 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 229960000932 candesartan Drugs 0.000 abstract 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 abstract 1
- 229960004563 eprosartan Drugs 0.000 abstract 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 abstract 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 abstract 1
- 229960005101 febuxostat Drugs 0.000 abstract 1
- 229960002198 irbesartan Drugs 0.000 abstract 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
- 229960004773 losartan Drugs 0.000 abstract 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005187 telmisartan Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 abstract 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una combinacion de principios activos, a saber de un inhibidor de xantina oxidasa como el febuxostat con uno o mrs antagonistas del receptor de angiotensina II, composiciones farmacéuticas que contienen a, dichos principios activos, para uso en el tratamiento terapéutico de la hipertension humana o veterinaria y métodos para su preparacion. Reivindicacion 4: La combinacion, de acuerdo con cualesquiera reivindicaciones 1 a 3, en la cual dicho antagonista del receptor de angiotensina II está seleccionado a partir del grupo que comprende: olmesartán medoximil, candesartán, eprosartán, irbesartán, losartán, telmisartán, valsartán o sus sales aceptables en el campo farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2010A000232A IT1400311B1 (it) | 2010-05-10 | 2010-05-10 | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081376A1 true AR081376A1 (es) | 2012-08-29 |
Family
ID=42753377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101590A AR081376A1 (es) | 2010-05-10 | 2011-05-09 | Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130131128A1 (es) |
| EP (1) | EP2568982B1 (es) |
| JP (1) | JP2013526503A (es) |
| KR (1) | KR20130101447A (es) |
| CN (1) | CN103037861A (es) |
| AR (1) | AR081376A1 (es) |
| AU (1) | AU2011252151A1 (es) |
| BR (1) | BR112012028887A2 (es) |
| CA (1) | CA2798573A1 (es) |
| CL (1) | CL2012003143A1 (es) |
| CO (1) | CO6640306A2 (es) |
| EA (1) | EA201201528A1 (es) |
| EC (2) | ECSP12012332A (es) |
| IL (1) | IL222927A0 (es) |
| IT (1) | IT1400311B1 (es) |
| MA (1) | MA34297B1 (es) |
| MX (1) | MX2012013054A (es) |
| NZ (1) | NZ603414A (es) |
| PE (1) | PE20130812A1 (es) |
| PH (1) | PH12012502198A1 (es) |
| SG (1) | SG185474A1 (es) |
| TW (1) | TW201206432A (es) |
| WO (1) | WO2011141431A1 (es) |
| ZA (1) | ZA201209295B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3028371B1 (fr) * | 2014-11-06 | 2016-11-18 | Bull Sas | Procede de surveillance et de controle deportes d'un cluster utilisant un reseau de communication de type infiniband et programme d'ordinateur mettant en oeuvre ce procede |
| JP2018135278A (ja) * | 2017-02-20 | 2018-08-30 | 株式会社スタージェン | 循環器疾患及び／又はミトコンドリア病の改善用医薬 |
| KR102284764B1 (ko) | 2020-07-08 | 2021-08-04 | 주식회사 우드메탈 | 멀티빔구조를 통한 부속의 결속이 용이한 칸막이 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2092580T3 (es) | 1990-11-30 | 1996-12-01 | Teijin Ltd | Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo. |
| IE920540A1 (en) | 1991-02-21 | 1992-08-26 | Sankyo Co | 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use |
| HU230799B1 (hu) | 1998-06-19 | 2018-06-28 | Teijin Pharma Limited | 2-(3-Ciano-4-izobutiloxifenil)-4-metil-5-tiazolkarbonsav polimorf módosulatai és eljárás ezek előállítására |
| EP1595540A1 (en) | 2000-11-21 | 2005-11-16 | Sankyo Company Limited | Composition containing an angiotensin II receptor antagonist and a diuretic and its use for the treatment of hypertension |
| US20040122067A1 (en) | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
| WO2004067003A1 (ja) | 2003-01-31 | 2004-08-12 | Sankyo Company, Limited | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
| WO2005027887A2 (en) * | 2003-09-17 | 2005-03-31 | Cardimone Pharma Corporation | Methods and compositions for improving endothelial function |
| US20070167454A1 (en) * | 2005-08-03 | 2007-07-19 | Christopher Lademacher | Methods for treating hypertension |
| JP2009516691A (ja) | 2005-11-21 | 2009-04-23 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | Ｑｔ間隔延長およびこれに伴う疾病の治療 |
| AU2007323919A1 (en) | 2006-11-13 | 2008-05-29 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preserving renal function using xanthine oxidoreductase inhibitors |
-
2010
- 2010-05-10 IT ITRM2010A000232A patent/IT1400311B1/it active
-
2011
- 2011-05-09 MX MX2012013054A patent/MX2012013054A/es not_active Application Discontinuation
- 2011-05-09 PH PH1/2012/502198A patent/PH12012502198A1/en unknown
- 2011-05-09 CA CA2798573A patent/CA2798573A1/en not_active Abandoned
- 2011-05-09 EP EP11718734.4A patent/EP2568982B1/en not_active Not-in-force
- 2011-05-09 MA MA35430A patent/MA34297B1/fr unknown
- 2011-05-09 AR ARP110101590A patent/AR081376A1/es unknown
- 2011-05-09 BR BR112012028887A patent/BR112012028887A2/pt not_active IP Right Cessation
- 2011-05-09 KR KR1020127032188A patent/KR20130101447A/ko not_active Withdrawn
- 2011-05-09 NZ NZ603414A patent/NZ603414A/en not_active IP Right Cessation
- 2011-05-09 PE PE2012002151A patent/PE20130812A1/es not_active Application Discontinuation
- 2011-05-09 CN CN2011800232573A patent/CN103037861A/zh active Pending
- 2011-05-09 US US13/697,066 patent/US20130131128A1/en not_active Abandoned
- 2011-05-09 WO PCT/EP2011/057438 patent/WO2011141431A1/en not_active Ceased
- 2011-05-09 EA EA201201528A patent/EA201201528A1/ru unknown
- 2011-05-09 TW TW100116119A patent/TW201206432A/zh unknown
- 2011-05-09 JP JP2013509533A patent/JP2013526503A/ja not_active Abandoned
- 2011-05-09 SG SG2012082319A patent/SG185474A1/en unknown
- 2011-05-09 AU AU2011252151A patent/AU2011252151A1/en not_active Abandoned
-
2012
- 2012-11-08 IL IL222927A patent/IL222927A0/en unknown
- 2012-11-08 CL CL2012003143A patent/CL2012003143A1/es unknown
- 2012-12-07 ZA ZA2012/09295A patent/ZA201209295B/en unknown
- 2012-12-10 CO CO12223245A patent/CO6640306A2/es not_active Application Discontinuation
- 2012-12-10 EC ECSP12012332 patent/ECSP12012332A/es unknown
- 2012-12-10 EC ECSP12012331 patent/ECSP12012331A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103037861A (zh) | 2013-04-10 |
| MX2012013054A (es) | 2013-03-05 |
| KR20130101447A (ko) | 2013-09-13 |
| ZA201209295B (en) | 2013-08-28 |
| CL2012003143A1 (es) | 2013-06-21 |
| MA34297B1 (fr) | 2013-06-01 |
| TW201206432A (en) | 2012-02-16 |
| US20130131128A1 (en) | 2013-05-23 |
| EA201201528A1 (ru) | 2013-04-30 |
| ECSP12012332A (es) | 2013-02-28 |
| PE20130812A1 (es) | 2013-08-08 |
| EP2568982B1 (en) | 2014-04-02 |
| SG185474A1 (en) | 2012-12-28 |
| ECSP12012331A (es) | 2013-02-28 |
| EP2568982A1 (en) | 2013-03-20 |
| BR112012028887A2 (pt) | 2016-07-26 |
| PH12012502198A1 (en) | 2013-02-25 |
| JP2013526503A (ja) | 2013-06-24 |
| IL222927A0 (en) | 2012-12-31 |
| AU2011252151A1 (en) | 2012-11-29 |
| CA2798573A1 (en) | 2011-11-17 |
| ITRM20100232A1 (it) | 2011-11-11 |
| NZ603414A (en) | 2014-03-28 |
| IT1400311B1 (it) | 2013-05-24 |
| WO2011141431A1 (en) | 2011-11-17 |
| CO6640306A2 (es) | 2013-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Michel et al. | A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists | |
| CO6400170A2 (es) | Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos | |
| CL2011002180A1 (es) | Compuestos derivados de benzimidazol, inhibidores de mpges-1; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y dolor. | |
| DOP2012000105A (es) | Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes | |
| DOP2011000260A (es) | Pirimidinas fusionadas | |
| CL2011002825A1 (es) | Compuestos derivados de bencimidazol heteroarilo sustituido; composición farmacéutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
| ECSP12012270A (es) | Compuestos de pirazol como inhibidores del receptor sigma | |
| ECSP11011294A (es) | Compuestos de anillo fusionados y su uso | |
| CR20110596A (es) | Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas | |
| DOP2015000189A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| SV2011003853A (es) | Compuestos organicos | |
| ECSP109965A (es) | Imidazoles fusionados para el tratamiento del cancer | |
| UA107784C2 (en) | Inhibitor of melanin production | |
| CL2010001361A1 (es) | Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension. | |
| MX345032B (es) | Antagonistas del receptor ep4 para el tratamiento de cáncer. | |
| CL2011000625A1 (es) | Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida. | |
| WO2012001065A3 (en) | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor | |
| WO2010116282A8 (en) | 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses | |
| EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения | |
| BR112016005589B8 (pt) | Composição farmacêutica líquida, e, uso da mesma | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| PE20151782A1 (es) | Derivados de azaquinolin-carboxamida | |
| AR081376A1 (es) | Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso | |
| ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
| CR20120617A (es) | Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |